Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Rein Therapeutics, Inc. (RNTX)

Rein Therapeutics posts LTI-03 investor presentation with Phase 1b and Phase 2 trial details

Neutral Impact 2 of 5 other Written later

Rein Therapeutics published an investor presentation on its website on September 4, 2026, covering its LTI-03 candidate for idiopathic pulmonary fibrosis (IPF). The filing is a Regulation FD disclosure with no new financial results, and the presentation restates earlier trial data and says the RENEW Phase 2 trial is now enrolling.

Key points

  • Phase 1b trial: 10mg and 5mg doses were well tolerated with no treatment-related serious adverse events (SAEs).
  • Plasma surfactant protein D fell 4.6% over two weeks at the 10mg dose (p=0.111; exploratory).
  • Presentation says present cash may fund operations into the first quarter of 2028.
  • RENEW Phase 2 trial (NCT06968845) is now enrolling.

The filing

CompanyRein Therapeutics, Inc. (RNTX)
Form8-K, current report
Filed with the SECSep 4, 2026, 4:31 PM ET
Accession number0001193125-26-383726

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.